Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1989 1
1990 1
1991 1
1992 1
1993 3
1994 2
1995 2
1996 4
1997 2
1998 2
1999 5
2000 4
2001 5
2002 4
2003 2
2004 3
2006 6
2007 1
2008 9
2009 2
2010 4
2011 5
2012 3
2013 4
2014 4
2015 7
2016 11
2017 9
2018 6
2019 2
2020 3
2021 4
2022 6
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Kakeji Y, et al. Among authors: ichikawa w. Gastric Cancer. 2022 Jan;25(1):188-196. doi: 10.1007/s10120-021-01224-2. Epub 2021 Aug 5. Gastric Cancer. 2022. PMID: 34351555 Clinical Trial.
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Yoshida K, et al. Among authors: ichikawa w. J Clin Oncol. 2019 May 20;37(15):1296-1304. doi: 10.1200/JCO.18.01138. Epub 2019 Mar 29. J Clin Oncol. 2019. PMID: 30925125 Free PMC article. Clinical Trial.
MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival.
Hurd M, Pino J, Jang K, Allevato MM, Vorontchikhina M, Ichikawa W, Zhao Y, Gates R, Villalpando E, Hamilton MJ, Faiola F, Pan S, Qi Y, Hung YW, Girke T, Ann D, Seewaldt V, Martinez E. Hurd M, et al. Among authors: ichikawa w. Genes Dev. 2023 Oct 1;37(19-20):865-882. doi: 10.1101/gad.350736.123. Epub 2023 Oct 18. Genes Dev. 2023. PMID: 37852796 Free PMC article.
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.
Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, Sunakawa Y, Takeuchi M, Fujii M. Kodera Y, et al. Among authors: ichikawa w. Gastric Cancer. 2023 Nov;26(6):1063-1068. doi: 10.1007/s10120-023-01419-9. Epub 2023 Aug 7. Gastric Cancer. 2023. PMID: 37548812 Free PMC article. Clinical Trial.
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M. Kawakami H, et al. Among authors: ichikawa w. Eur J Cancer. 2023 May;184:10-20. doi: 10.1016/j.ejca.2023.02.003. Epub 2023 Feb 10. Eur J Cancer. 2023. PMID: 36889037
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.
Yasui H, Okita Y, Nakamura M, Sagawa T, Watanabe T, Kataoka K, Manaka D, Shiraishi K, Akazawa N, Okuno T, Shimura T, Shiozawa M, Sunakawa Y, Ota H, Kotaka M, Okuyama H, Takeuchi M, Ichikawa W, Fujii M, Tsuji A. Yasui H, et al. Among authors: ichikawa w. ESMO Open. 2023 Oct;8(5):101636. doi: 10.1016/j.esmoop.2023.101636. Epub 2023 Sep 12. ESMO Open. 2023. PMID: 37703596 Free PMC article. Clinical Trial.
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M. Kawabata R, et al. Among authors: ichikawa w. Target Oncol. 2023 May;18(3):359-368. doi: 10.1007/s11523-023-00961-x. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060430 Clinical Trial.
RAS mutations in colorectal cancer.
Sunakawa Y, Lenz HJ, Ichikawa W. Sunakawa Y, et al. Among authors: ichikawa w. N Engl J Med. 2013 Nov 28;369(22):2159. doi: 10.1056/NEJMc1312697. N Engl J Med. 2013. PMID: 24283233 No abstract available.
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.
Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, Takeuchi M, Ichikawa W, Fujii M. Tsuji A, et al. Among authors: ichikawa w. Target Oncol. 2021 Nov;16(6):753-760. doi: 10.1007/s11523-021-00845-y. Epub 2021 Oct 31. Target Oncol. 2021. PMID: 34718946 Review.
128 results